Psoriasis Longitudinal Assessment and Registry

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2007
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. The study also includes patients receiving other therapies, such as non-biologic and other biologic agents. The registry also evaluates patient and disease characteristics, including patient-reported assessment of psoriatic arthritis (PsA); and clinical and quality of life outcomes.
Epistemonikos ID: 2303acff9ff30306601e34fffe8da8f059ed7a3a
First added on: Feb 15, 2022